TY - JOUR
T1 - Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study
AU - Bongiorno, Maria Rita
AU - Costanzo, null
AU - Marzano, Angelo Valerio
AU - Prignano, null
AU - Dini, Valentina
AU - Fania, null
AU - Bianchini, null
AU - Bettoli, null
AU - Casazza, Giovanni
AU - Genovese, null
AU - Bianchi, Luca
AU - Cannavò, Salvatore
AU - Atzori, null
AU - Moltrasio, null
AU - Bianchini, null
AU - Cannavò, Serafinella
AU - Fabbrocini, Gabriella
AU - Sirna, null
AU - Dapavo, null
AU - Fabbrocini, null
AU - Offidani, null
AU - Micali, Giuseppe
AU - Peris, Ketty
AU - Patrizi, Annalisa
AU - Venturini, Marina
AU - Gisondi, null
AU - De Patrizio, Alessandro
AU - Sirna, Rosa
AU - Medini, Viviana
PY - 2020
Y1 - 2020
N2 - The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
AB - The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
UR - http://hdl.handle.net/10447/401854
M3 - Article
SN - 0007-0963
JO - British Journal of Dermatology
JF - British Journal of Dermatology
ER -